Pneumagen Targeting The Human Glycome To Block Viral Entry

COVID-19 Among Potential Uses

Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.  

Emerging Company Profile Regular column feature image Version 2

The UK start-up Pneumagen Ltd has been working on a novel way of blocking the entry of pathogens including influenza and coronaviruses into human cells, and expects to start clinical studies with its lead product, Neumifil, a multivalent protein, in 2021.

The technology under development by Pneumagen has its origins in research conducted more than 10 years ago at St Andrews...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Emerging Company Profiles

More from Start-Ups & SMEs